GOVERNANCE
ICN is led by a Steering Board consisting of representatives of all ten core members. The Steering Board is the responsible, decision-making body. The Steering Board also decides on memberships and services offered. The chairperson of the Steering Board is elected for a period of two years.
| Dr med Christiane Blankenstein | Director Münchner Studienzentrum, Hospital rechts der Isar, Technical University of Munich Munich |
| Associate Prof Dr Tsutomu Nishimura |
Institute for Advancement of Clinical and Translational Science, Kyoto University Hospital Kyoto |
| C. Michael Gibson (MD) | President Baim Institute for Clinical Research Boston |
| Prof Dr Ian Wilkinson | Director Cambridge Clinical Trial Unit, Cambridge University Hospitals NHS Foundation Trust Cambridge |
| Dr phil Britta Lang | Director Clinical Trials Unit Freiburg, Albert-Ludwigs-University of Freiburg Freiburg |
| Henry Yau |
Managing Director Clinical Trials Centre, The University of Hong Kong Hong Kong |
| Prof Dr Semra Demokan | Director Center of Excellence for Clinical Research, Istanbul University Istanbul |
| Prof Dr Rongxing Gan | President and CEO Shanghai Clinical Research Center Shanghai |
| Eugene Gan, PhD | Senior Director Singapore Clinical Research Institute Singapore |
| Dr med Regina Grossmann | Head Clinical Trials Center Zurich, University Hospital Zurich Zurich |
SCIENTIFIC ADVISORY BOARD
The Steering Board may appoint suitable individuals to the Scientific Advisory Board on the recommendation of the Chair and the Vice chair. Scientific Advisory Board members would fulfil a senior advisory role to the ICN leadership and Steering Board. They may be invited to participate in ICN workgroups based on their expertise and interest, and may be invited to attend Steering Board meetings in a non-voting capacity. Scientific Advisory Board members should be former members of the ICN or of ICN member centres.
| Professor Dr. med. Gabriela Senti | Director, Research and Education, University Hospial Zurich Founder of ICN Former ICN Chairperson (2015-17) |
| Professor Muneo Takatani | Senior Adviser, Office of Society-Academia Collaboration for Innovation, Kyoto University Former ICN Steering Board Member |
| Dr Thomas Hiemstra | Honorary Consultant Nephrologist, Cambridge Clinical Trials Unit, Cambridge University Hospitals NHS Foundation Trust Former ICN Chairperson (2019-20) |
| Prof Yagiz Uresin | Head of Department of Medical Pharmacology, Istanbul Faculty of Medicine Former ICN Chairperson (2017-19) |
OPERATIONS
The ICN operates as much as possible on a decentralized basis. The Operations Team manages common operations and processes. Currently, ICN represents network without a legal entity. However, the Steering Board, as the highest decision making body of the ICN, will pursue adherence to agreed strategies, principles and standards. With the current informal legal status of ICN, there are no financial obligations of members to the ICN organization or its leadership. Payable services will be contracted and settled bilaterally between the providing and the consuming partners.
| Dr Anja Eskat | ICN Operations Team Lead |
| Annina Bauer | ICN Operations Officer |
| Antonia Galliker | ICN Operations Officer |
| Michelle Sonderer | ICN Operations Officer |
| Cathy Shen | ICN Operations Officer |
| Dana Lin | ICN Operations Officer |
PAST CHAIRPERSONS
| 2015-17 | 2017-19 | 2019-20 | 2020-22 | |||
| Prof Dr. med. Gabriela Senti | Prof Dr Yagiz Üresin | Dr Thomas Hiemstra | Henry Yau |